Biopharmx Corp (NYSEMKT:BPMX) Presents Poster At American Academy of Dermatology Annual Meeting Suggesting BPX-01 Safely, Efficiently Delivers Acne-Fighting Minocycline To Pilosebaceous Units

0
445
top biotech stocks

Biopharmx Corp (NYSEMKT:BPMX), a leading and top biotech stocks pharmaceutical company that specializes in development dermatology products market, will be announcing pre-clinical and clinical information at this year’s Annual Meeting of the American Academy of Dermatology (AAD). The company will be seeking to prove the working of its topical gel BPX-01 as a solution to offer treatment for Acne to a target area without side effects.

The company will make available a post for sharing the research for viewing at the exhibition which is scheduled for March 3rd to 6th. The poster will be titled “Development and Assessment of BPX-01, a Novel Topical Minocycline Gel for Treatment of Acne Vulgaris,”

Usha Nagavarapu a Senior Director of Preclinical Drug Development at BioPharmX will deliver a public presentation to elaborate on the poster on March 3. The Annual Meeting of the American Academy of Dermatology which will take place in Orlando, Fla is one of the biggest global gathering of dermatologists.

Oral minocycline is used in the treatment of acne but due to its systematic mode of delivery, users sometimes experience undesirable side effects like diarrhea, upset stomach, headache and dizziness. BPX-01 is the first minocycline appearing in gel form which can be used in lower dosages.

According to Dr. Ted Lain, an investigator on the study of BioPharmX Phase 2b of BPX-01 and a certified dermatologist says the use of ‘Holy Grail’ in treating acne helps in optimizing both tolerability and efficacy. He adds that dermatologists require a product which can be administered efficiently without side effects.

BPX-01[1] is the only available stable hydrophilic gel with soluble minocycline that can easily deliver the antibiotic by easily penetrating the skin to spots with acne. BioPharmX’s clinical and pre-clinical studies are aimed at establishing whether BPX-01 can conclusively treat acne with safer and lower dosages of the antibiotic.

The company is currently carrying out an OPAL study. This is a Phase 2b clinical study to determine the safety and efficacy of BPX-01 in the treatment of acne vulgaris.

LEAVE A REPLY

Please enter your comment!
Please enter your name here